Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc. (ELOXD): 3 pipeline candidates · ~4 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.9 months
850% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for Eloxx Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$43.8M
Cash
$6.4M
Quarterly Burn
$5.5M
Runway
3.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in Eloxx Pharmaceuticals, Inc.'s pipeline?
Eloxx Pharmaceuticals, Inc. (ELOXD) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Eloxx Pharmaceuticals, Inc.'s lead drug candidate?
Eloxx Pharmaceuticals, Inc.'s most advanced tracked candidate is elx-02 (Phase 2) for Alport Syndrome.
What is Eloxx Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Eloxx Pharmaceuticals, Inc. has approximately 3.9 months of cash runway.
What is Eloxx Pharmaceuticals, Inc.'s market capitalization?
Eloxx Pharmaceuticals, Inc.'s market capitalization is approximately $43.8M.
Who is the CEO of Eloxx Pharmaceuticals, Inc.?
Mr. Sumit Aggarwal M.B.A. is the chief executive officer of Eloxx Pharmaceuticals, Inc. (ELOXD).
Get the full picture on Eloxx Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.